CA-ESRI
24.6.2021 14:02:10 CEST | Business Wire | Press release
Esri , the global leader in location intelligence, today announced it is releasing for the first time ever a new high-resolution, 2020 global land cover map as part of the company’s Living Atlas . The map was built using European Space Agency (ESA) Sentinel-2 satellite imagery, and developed using a new machine learning workflow teaming with new Esri Silver Partner Impact Observatory , as well as long-time partner Microsoft.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005176/en/
The new map will be updated annually supporting change detection and highlighting planetary land changes, especially related to the effects of human activity. A consistent map of land cover for the entire world based on the most current satellite information, the 2020 Global Land Cover Map can be combined with other data layers for green infrastructure, sustainability projects, and other conservation efforts that require a holistic picture of both the human and natural footprint on the planet. Later this year, Esri and Impact Observatory will make this new land cover model available to support on-demand land cover classification, allowing the GIS community to create maps for project areas as often as every week.
"This is a critical year for climate action," said Jack Dangermond, Esri founder and president. "With the UN Climate Change Conference of the Parties (COP26) bringing international parties together to address a set of common goals, we are happy to do our part in making this map available to users that are working towards the health of our planet."
Users will also be able to manipulate the map in association with other GIS layers such as terrain, hydrology, and more, all available in ArcGIS Living Atlas of the World, the foremost collection of geographic information from around the globe, including maps, apps, and data layers. Through the visualizations being released, planners worldwide will better understand the geography around them to make more informed decisions—enabling them to gain insight into locations with distinctive land cover, as well as human activity affecting them.
High-resolution, open, accurate, comparable, and timely land cover maps are critical for decision-makers in many industry sectors and developing nations. These maps improve understanding of important topics such as food security, land use planning, hydrology modeling, and resource management planning. In addition, national government resource agencies use land cover as a basis for understanding trends in natural capital, which helps define land planning priorities and is the basis of budget allocations.
Impact Observatory, contracted by Esri, developed a deep learning AI land classification model using a massive training dataset of billions of human-labeled image pixels, and applied this model to the Sentinel-2 2020 scene collection, processing over 400,000 Earth observations to produce the map. The unique machine learning approach used to create this global map will soon be available on demand, supporting land managers who need to monitor change in a specific area of interest, looking at annual change and seasonal differences in land cover.
"Global efforts are urging world leaders to set and achieve ambitious conservation targets," said Steve Brumby, Impact Observatory co-founder and CEO. "With support from the geospatial experts at Esri, and access to incredible compute resources at Microsoft, we were able to build in record time a land cover map that provides leaders in governments, NGOs, and across industries with a novel, timely view of the planet, and a new AI-powered capability for actionable, science-based insights on demand. In doing so, Impact Observatory hopes to contribute towards the global conservation effort."
Esri is releasing this valuable resource under a Creative Commons license to encourage broad adoption and ensure equitable access for planners creating a more sustainable planet. This content will be made available in ArcGIS Online as a map service and be freely available for use by its 10 million users. It will also be available for download and viewing. To explore the new 2020 Global Land Cover Map, visit livingatlas.arcgis.com/landcover .
About Impact Observatory
Impact Observatory is a mission-driven technology company bringing artificial intelligence (AI) powered algorithms and on-demand data to sustainability and environmental risk analysis for governments, non-profit organizations, companies, and markets. Founded in 2020 in Washington, DC, Impact Observatory’s goal is to empower global decision-makers to be planetary superheroes, with the timely, actionable science-based insights they need to succeed. Visit us at impactobservatory.com .
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2021 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005176/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom